CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)
Japan's national programme tests whether a blood test after surgery should decide who gets chemotherapy, and whether treating a positive test early helps.
GALAXY (observational, >2,000 patients) showed ctDNA positivity 4 weeks post-surgery is the strongest predictor of recurrence (Nature Medicine 2023). ALTAIR (ctDNA-positive, randomised to trifluridine/tipiracil vs placebo) missed its DFS endpoint (2024), suggesting late-line chemotherapy does not clear MRD. VEGA (ctDNA-negative, omit vs give CAPOX) is ongoing. Together with DYNAMIC these define the state of ctDNA-guided adjuvant therapy in CRC.
Pages like this
not linked directly; found by shared links- Key paperGALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold
Shares ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer, Takayuki Yoshino, Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials, Signatera.
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares DYNAMIC, Signatera, Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease.
- Key paperDYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer
Shares ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer, DYNAMIC, Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease.
- TrialIMvigor011
Shares A national platform trial that every ctDNA-positive patient can join, Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials, Signatera, Metastasis is understood least and studied last.
- PairingctDNA MRD → adjuvant therapy decision
Shares Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials, DYNAMIC, Signatera, Minimal / molecular residual disease (MRD).
- IdeaBreak the neutrophil DNA nets that catch tumour cells after surgery
Shares Metastasis is understood least and studied last, Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- InstitutionAustralasian Gastro-Intestinal Trials Group
Shares DYNAMIC, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- InstitutionNational Cancer Center Hospital East
Shares Takayuki Yoshino, National Cancer Center Hospital, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD).